Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

Vaccine

Volumn 15, Issue 11, 1997, Pages 1209-1213

  Ambrosch, F ^a   Wiedermann, G ^a   Jonas, S ^a   Althaus, B ^b   Finkel, B ^b   Gluck R ^b   Herzog, C ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b Berna Biotech AG   (Switzerland)

Author keywords

Immunogenicity; Liposomal hepatitis A vaccine; Virus neutralizing antibodies

Indexed keywords

HEPATITIS A VACCINE; LIPOSOME; VIRUS HEMAGGLUTININ;

ADULT; ARTICLE; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEADACHE; HEPATITIS A; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEROCONVERSION;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HEPATITIS ANTIBODIES; HUMANS; LINEAR MODELS; LIPOSOMES; MALE; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

EID: 0030819524     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00015-7     Document Type: Article

References (33)

1. Gust, I.D. Epidemilogical patterns of hepatitis A in different parts of the world. Vaccine 1992, 10, 56-58.
2. André, F.E. Development of a vaccine against hepatitis A. In Viral Hepatitis and Liver Diseases (Eds Hollinger, B., Lemon, S.M. and Margolis, H.S.). Williams and Wilkins, Baltimore, 1991, pp. 85-88.
3. Wiedermann, G., Ambrosch, F. and Kollaritsch, H. et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 1990, 8, 581-584.
4. Ambrosch, F., Wiedermann, G., André, F.E., d'Hondt, E., Delem, A. and Safary, A. Comparison of HAV antibodies induced by vaccination and natural infection. In Viral Hepatitis and Liver Diseases (Eds Hollinger, B., Lemon, S.M. and Margolis, H.S.). Williams and Wilkins, Baltimore, 1991, pp. 98-100.
5. Ambrosch, F., André, F.E. and Delem, A. et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine 1992, 10, 129-131.
6. Wiedermann, G., Ambrosch, F., André, F.E., d'Hondt, E., Delem, A. and Safary, A. Persistence of vaccine-induced anti-HAV antibodies. Vaccine 1992, 10, 142-145.
7. Ambrosch, F., Wiedermann, G. and André, F.E. et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J. Med. Virol. 1994, 44, 452-456.
8. Wiedermann, G. and Ambrosch, F. Immunogenicity of an inactivated hepatitis A vaccine after exposure at 37°C for 1 week. Vaccine 1994, 12, 401-402.
9. Ambrosch, F., Jonas, S., Kunz, Ch., André, F. and Wiedermann, G. Active immunization against hepatitis A. Vaccination strategies and future perspectives. Trop. Med. Parasitol. 1994, 45, 145.
10. Van Damme, P., Mathei, C., Thoelen, S., Meheus, A., Safary, A. and André, F.E. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J. Med. Virol. 1994, 44, 435-441.
11. Briem, H. and Safary, A. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J. Med. Virol. 1994, 44, 443-445.
12. Werzberger, A., Mensch, B. and Kuter, B. et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med. 1992, 327, (7), 453-457.
13. Block, S., Hedrick, J.A. and Tyler, R.D. et al. Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA®) in rural Kentucky children. Pediatr. Infect. Dis. J. 1993, 12, 976-980.
14. Shouval, D., Ashur, Y. and Adler, R. et al. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine 1993, 11, S9-S14.
15. Glück, R., Althaus, B., Berger, R., Just, M. and Cryz, S.J. Development, safety and immunogenicity of new inactivated hepatitis A vaccines: effects of adjuvants. In Travel Medicine (Eds Lobel, H.O., Steffen, R. and Kozarsky, P.E.). International Society of Travel Medicine, Atlanta, 1992, pp. 135-136.
16. Argentini, C., D'Ugo, E., Bruni, R., Glück, R., Giuseppetti, R. and Rapicetta, M. Sequence and phylogenetic analysis of the VP1 gene in two cell culture-adapted HAV strains from a unique pathogenic isolate. Virus Genes 1995, 10, 37-43.
17. Glück, R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 1992, 10, 915-919.
18. Glück, R., Mischler, R., Brantschen, S., Just, M., Althaus, B. and Cryz, S.J. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 1992, 90, 2491-2495.
19. Glück, R. Liposomal presentation of antigens for human vaccines. In Vaccine Design: The Subunit and Adjuvant Approach (Eds Powell, M.F. and Newman, M.J.). Plenum Press, New York, 1995, pp. 325-345.
20. Just, M., Berger, R., Drechsler, H., Brantschen, S. and Glück, R. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine 1992, 10, 737-739.
21. Frösner, G.G., Dathe, O., Althaus, B. et al. Hohe Immunogenität und geringe Nebenwirkungen eines neuartigen Liposomenimpfstoffes gegen Hepatitis A. In Virushepatitis A bis E - Diagnose, Therapie, Prophylaxe; Kongressberichte des Deutschen Grünen Kreuzes (Eds Maass, G. and Stück, B.). Kilian Verlag Marburg, 1994, pp. 222-224.
22. Loutan, L., Bovier, P., Althaus, B. and Glück, R. Inactivated virosome hepatitis A vaccine. Lancet 1994, 343, 322-324.
23. Wegmann, A., Zellmeyer, N. and Glück, R. et al. Immunogenität und Stabilität eines aluminiumfreien liposomalen Hepatitis-A-Impfstoffes (Epaxal Berna®). Schweiz, med. Wschr. 1994, 124, 2053-2056.
24. Ambrosch, F., Althaus, B., Glück, R., Herzog, Ch., Jonas, S. and Wiedermann, G. Immunogenität und Protektivität eines inaktivierten Hepatitis A-Impfstoffes auf Liposomenbasis. Mitt. Österr. Ges. Tropenmed. Parasitol. 1995, 17, 201-208.
25. Poovorawan, Y., Theamboonlers, A., Chumdermpadetsuk, S., Glück, R. and Cryz, S.J. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 1995, 13, 891-893.
26. Simmen, H.P., Robustelli, L., Althaus, B., Glück, R., Trentz, O. and Vogt, M. Immunantwort einer Einzeldosis eines neuartigen Hepatitis A-Impfstoffes nach Splenektomie. Dtsch. med. Wschr. 1996, 121, 295-298.
27. Holzer, B.R., Hatz, Ch., Schmidt-Sissolak, D., Glück, R., Althaus, B. and Egger, M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 1996, 14, 982-986.
28. André, F.E., d'Hondt, E., Delem, A. and Safary, A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992, 10, 160-168.
29. Innis, B.L., Snitbhan, R. and Kunasol, P. et al. Protection against hepatitis A by an inactivated vaccine. J. Am. Med. Assoc. 1994, 271, 1328-1334.
30. Vidor, E., Xueref, C., Bajard, A. and Fanget, B. Analysis of the immune response of volunteers after vaccination with Pasteur Mérieux inactivated hepatitis A vaccine. Am. J. Trop. Med. Hyg. 1994, 51, 142.
31. CDC, licensure of inactivated hepatitis A vaccine and recommendations for use among international travelers. Morbid. Mortal. Wkly Rep. 1995, 44, 559-560.
32. Burkardt, F., Glück, R., Finkel-Jimenez, B. and Brantschen, S. Hepatitis A-vaccines: a comparison between three methods of antigen determination. In Replacement, Reduction and Refinement of Animal Experiments in the Development and Control of Biological Products. Developments in Biological Standardization, Vol. 86 (Eds Brown, F., Cussler, K. and Hendriksen, C.). Karger, Basel, 1996, pp. 129-135.
33. Reed, L.J. and Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27, 493-497.